Li Minghui, Cao Weihua, Jiang Tingting, Deng Wen, Wang Shiyu, Wu Shuling, Zhang Lu, Lu Yao, Chang Min, Liu Ruyu, Ding Xiaoyan, Shen Ge, Gao Yuanjiao, Hao Hongxiao, Chen Xiaoxue, Hu Leiping, Xu Mengjiao, Jiang Yuyong, Yi Wei, Xie Yao, Song Rui
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China.
Biosaf Health. 2024 Apr 30;6(3):165-170. doi: 10.1016/j.bsheal.2024.04.004. eCollection 2024 Jun.
To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone ( = 0.003) and immunosuppressant ( = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients ( = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group ( = 0.018). Logistic regression analysis showed that UDCA use ( = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use ( = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group ( = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.
探讨熊去氧胆酸（UDCA）对自身免疫性肝病（AILD）患者严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染及临床结局的影响。纳入诊断为AILD的患者，根据是否接受UDCA治疗分为UDCA组和非UDCA组。收集有关AILD诊断、治疗、生化指标及影像学检查的相关数据。观察SARS-CoV-2感染的发生率及AILD患者的预后。共有1138例患者完成随访。非UDCA组用于治疗AILD的激素（P = 0.003）和免疫抑制剂（P = 0.001）使用率明显低于UDCA组。SARS-CoV-2感染患者的UDCA使用率明显低于未感染患者（P = 0.003）。非UDCA组的SARS-CoV-2感染率明显高于UDCA组（P = 0.018）。Logistic回归分析显示，使用UDCA（P = 0.003）与较低的SARS-CoV-2发病率相关，而使用免疫抑制剂（P = 0.017）则增加发病率。接受UDCA治疗的患者从SARS-CoV-2感染中恢复的时间明显长于非UDCA组（P = 0.018）。UDCA与AILD患者低SARS-CoV-2发病率相关，而免疫抑制剂则增加其发病率。接受UDCA治疗的患者感染后恢复时间更长。
